Health & Medicine Theories

Merck launched the painkiller Vioxx (rofecoxib) in 1999 despite internal data suggesting elevated cardiovascular risk. The VIGOR trial (2000) showed a five-fold increase in heart attacks versus naproxen; Merck downplayed the finding for four years. APPROVe (2004) confirmed the risk and Merck withdrew Vioxx globally. The FDA estimated 27,000 to 55,000 excess cardiovascular deaths during the drug's five years on the market. Merck settled MDL 1657 for $4.85 billion in 2007. Internal emails show executives debating how to "handle" the cardiovascular signal. This is a confirmed corporate concealment, not a disputed claim.

Theranos, founded by Elizabeth Holmes in 2003, claimed its proprietary Edison device could run hundreds of diagnostic tests from a single finger-prick of blood. The technology never worked as claimed. A 2015 Wall Street Journal investigation by John Carreyrou exposed the fraud. The company voided two years of Edison-based test results, affecting approximately 176,000 patients. Holmes was convicted of four counts of wire fraud (January 2022, sentenced to 11 years). President Balwani was convicted of 12 counts (July 2022, sentenced to nearly 13 years). Patients received false medical results; some made clinical decisions based on inaccurate data.

JUUL Labs launched its e-cigarette in 2015 with marketing that regulators and litigants found deliberately targeted underage users: bright colours, social media influencers, flavoured pods, and campaigns that mirrored cigarette advertising strategies proven to recruit teen smokers. Between 2017 and 2019, teen e-cigarette use surged to epidemic levels — the FDA called it a "youth vaping epidemic." In June 2022, the FDA denied JUUL's marketing authorisation, citing inadequate safety data. In December 2022, JUUL settled a 33-state attorney general investigation for $462 million. Separate settlements with school districts and individual states totalled additional hundreds of millions. The targeting of minors is confirmed by internal documents, regulatory findings, and legal settlements.

GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) was approved by the FDA in 1999. A 2007 meta-analysis by cardiologist Steven Nissen, published in the New England Journal of Medicine, found that Avandia was associated with a 43% increased risk of myocardial infarction. Senate Finance Committee investigations in 2010 found that GSK had internal evidence of cardiovascular risk years before the Nissen publication and had not disclosed it to regulators. GSK settled with the US Department of Justice for $3 billion in 2012 — at the time the largest healthcare fraud settlement in US history — covering Avandia and other products. The FDA restricted Avandia to patients with no other options in 2010 and lifted the restrictions only in 2013 after further review.

A Reuters investigation published in December 2018 found that Johnson & Johnson knew for decades that its baby powder talc sometimes tested positive for asbestos, a known carcinogen, and did not disclose this to regulators or the public. Internal J&J documents dated from the 1970s through the early 2000s showed awareness of asbestos contamination in talc sourced from mines in Vermont and elsewhere. In 2018, a Missouri jury awarded $4.69 billion to 22 women who alleged asbestos-contaminated talc caused their ovarian cancer (Ingham v. Johnson & Johnson). J&J discontinued US and Canadian baby powder sales in 2020 and global sales in 2023. Two attempts to resolve talc liability through bankruptcy of a subsidiary (LTL Management) were rejected by federal courts in 2023.

The documented large-scale pharmaceutical cover-up of opioid addiction risk by Purdue Pharma (OxyContin), Insys (Subsys), Mallinckrodt, and related firms — contributing to over 700,000 US opioid-related deaths since 1999.

The 1950s-60s marketing of thalidomide (sedative, anti-nausea for pregnant women) by Chemie Grünenthal (Germany), Distillers (UK), and Richardson-Merrell (US) despite internal knowledge of risks, resulting in ~10,000 birth defects worldwide and a major documented corporate cover-up.

Internal documents proved that major tobacco companies knew cigarettes were addictive and caused cancer as early as the 1950s, while publicly denying both for decades. They funded fake research, suppressed internal findings, and targeted youth marketing. Settled via 1998 Master Settlement Agreement ($206 billion).

Forty-year (1932-1972) US Public Health Service study of 399 Black men with syphilis in Alabama. Researchers withheld treatment — even after penicillin became standard cure in 1947 — to observe the disease's progression. Exposed by whistleblower Peter Buxtun in 1972.